Series A financing will speed up development of therapies for drug-resistant infections

Biopharmaceutical company, Antabio, has completed a €7.3 million series A financing round for the development of novel therapies to treat drug-resistant gram-negative infections.

The financing was completed with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former president of OM Pharma Christophe Ricard. It will be used to accelerate the development and then up to completion of Phase I clinical trials of the company’s novel inhibitor of bacterial metallo ß-lactamases (MBLIs), which will be combined with carbapenem.

“We are delighted to welcome iXO Private Equity, Irdi Soridec and Galia Gestion to Antabio, and we are honoured by the continued solid support of our historical investors,” said Marc Lemonnier, CEO of Antabio. “This new financing, coupled with the non-dilutive funding recently received from CARB-X, will advance Antabio’s innovative programmes into clinical studies, thereby accelerating the development of our novel approaches to treat infections caused by WHO’s priority pathogens.”

“We initiate this collaboration with the Antabio team with a lot of enthusiasm,” added Jean-Michel Petit, investment director at IRDI Soridec Gestion. “Beyond the compelling medical need, we have been impressed with the professionalism of the team and the quality of the programmes developed at Antabio, which have already earned the support of global organisations such as the Wellcome Trust and CARB-X.”